Prior to joining UTMB in February, Dr. Landay most recently served as Vice Chair of Research and Division Chief of Translational and Precision Medicine in the Department of Internal Medicine at Rush University. Dr. Landay’s impressive career includes more than 42 years in HIV research, having performed some of the first immune evaluations of HIV-infected hemophiliacs in 1981. With Abbott Labs he helped develop the first HIV antibody test licensed by the FDA in 1985 for use in screening the blood supply. His laboratory has made important original contributions in understanding the role of immune activation and inflammation in outcomes of non-communicable disease related to aging in the HIV population.
For more than 30 years Dr. Landay has been an investigator for the Advancing Clinical Therapeutics Network (ACTG), a global clinical trials network that conducts research to improve the management of HIV and its comorbidities; develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis C, and emerging infectious diseases. Since its inception 20 years ago, he has led the Rush Immunology Support Lab.
Dr. Landay has extensive experience in aging-related studies. For the past 10 years, his research focus has been on studies of the human microbiome and metabolome and better understanding its role both in health and disease. More recently, Dr. Landay led the research effort for COVID-19 in the Department of Medicine at Rush, leading the establishment of the COVID-19 biorepository. He also leads the COVID-19 lab efforts for the NIH-funded ACTG Lab group. Additionally, he has extensive experience over the past 10 years working with laboratories in international settings in his role as Scientific Director of Labs for the NIH-funded ACTG Grant.